The polyphenol epigallocatechin-3-gallate (EGCG) inhibits the growth of cervical carcinoma cell lines potentially by altering the expression of micro-RNAs, indicating its potential as an anti-cervical cancer drug.
In the methodology, an MTT assay was used to measure cell proliferation and examine the inhibitory effects of EGCG, a polyphenol, on the growth of cervical carcinoma for HeLa cells subjected to a range of EGCG concentrations. The study also assessed the associated regulation of various microRNA expression involving HeLa, SiHa, CaSki and C33A cell lines, using quantitative polymerase chain reaction (PCR) analyses.
The results revealed that the growth of HeLa cells was significantly reduced by EGCG in a dose- and time-dependent manner. Further, the study found noteworthy changes in the expression of particular microRNAs in various cell lines due to EGCG treatment. It was observed that certain microRNAs were significantly downregulated while others were upregulated. Therefore, the study suggests that EGCG likely suppresses the growth of cervical carcinoma cells by potentially regulating the expression of micro-RNAs.
